Use of real-world evidence for oncology clinical decision making in emerging economies

被引:12
作者
Petracci, Fernando [1 ]
Ghai, Chirag [2 ]
Pangilinan, Andrew [2 ]
Suarez, Luis Alberto [3 ]
Uehara, Roberto [4 ]
Ghosn, Marwan [5 ,6 ]
机构
[1] Inst Alexander Fleming, Breast Canc Dept, Ave Cramer 1180, RA-1426 Buenos Aires, Argentina
[2] Real World Evidence Strategy & Solut, IQVIA, New York, NY 10282 USA
[3] Pfizer Inc, B1607EEV, Buenos Aires, DF, Argentina
[4] Pfizer Inc, New York, NY 10017 USA
[5] France Univ Hosp, Hotel Dieu, Hematol & Oncol Dept, Beirut, Lebanon
[6] St Joseph Univ, Beirut, Lebanon
关键词
Asia-Pacific; effectiveness; electronic database; health policy; Latin America; Middle East; randomized clinical trials; real-world data; real-world evidence; safety; RENAL-CELL CARCINOMA; CANCER-PATIENTS; SUNITINIB; PROGRESSION; RESISTANCE; EFFICACY; THERAPY; TRIALS; SAFETY; HEALTH;
D O I
10.2217/fon-2021-0425
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Lay abstract Traditionally, randomized clinical trials have been used to provide insights on new medical therapies and continue to remain the gold standard for approval. The-increasing availability of patient level data in the real-world, it is now possible to generate evidence regarding the usage and potential benefits or risks of a medical therapy derived from analysis of real-world data. This evidence is collectively referred to real-world evidence (RWE). randomized clinical trials and RWE are complementary and the area of Oncology especially benefits from RWE to guide clinical decision making across the patient journey. Key benefits include cancer screening and diagnosis, optimal treatment choices (including personalized medicine) and disease management such as dosing and treatment of side effects. In recent times, RWE generation in oncology has been prolific in the USA and western Europe. With expansive biopharmaceutical investments into infrastructure harnessing patient-level data and greater local regulatory guidance, oncology patients in emerging economies may now also have the opportunity to benefit from clinical decision making informed by RWE. Real-world evidence (RWE) can provide insights into patient profiles, disease detection, treatment choice, dosing strategies, treatment sequencing, adverse event management and financial toxicity associated with oncology treatment. However, the full potential of RWE is untapped in emerging economies due to structural and behavioral factors. Structural barriers include lack of regulatory engagement, real-world data availability, quality and integrity. Behavioral barriers include entrenched healthcare professional behaviors that impede rapid RWE understanding and adoption. These barriers can be addressed with close collaboration of healthcare stakeholders; of whom, regulators need to be at the forefront given their ability to facilitate use of RWE in healthcare policy and legislation.
引用
收藏
页码:2951 / 2960
页数:10
相关论文
共 50 条
  • [1] The relevance of the real-world evidence in research, clinical, and regulatory decision making
    Costa, Valton
    Custodio, Marcelo Graziano
    Gefen, Eran
    Fregni, Felipe
    FRONTIERS IN PUBLIC HEALTH, 2025, 13
  • [2] Real-world evidence: experiences and challenges for decision making in Latin America
    Garcia Marti, Sebastian
    Pichon-Riviere, Andres
    Augustovski, Federico
    Espinoza, Manuel
    INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2023, 39 (01)
  • [3] Awareness, Knowledge, and Utility of RCT Data vs RWE: Results From a Survey of US Cardiologists: Real-world Evidence in Clinical Decision Making
    Villines, Todd C.
    Cziraky, Mark J.
    Amin, Alpesh N.
    CLINICAL MEDICINE INSIGHTS-CARDIOLOGY, 2020, 14
  • [4] ,A review on generation of real-world evidence
    Shunmugavelu, Meenakshi Sundaram
    Panda, Jayanta Ku
    Sehgal, Ashish
    Makkar, Brij Mohan
    CLINICAL DIABETOLOGY, 2021, 10 (05): : 412 - 419
  • [5] The application of real-world evidence in drug regulatory decision-making
    Wicherski, Julia
    Haenisch, Britta
    BUNDESGESUNDHEITSBLATT-GESUNDHEITSFORSCHUNG-GESUNDHEITSSCHUTZ, 2024, 67 (02) : 255 - 256
  • [6] Real-world Data for Clinical Evidence Generation in Oncology
    Khozin, Sean
    Blumenthal, Gideon M.
    Pazdur, Richard
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2017, 109 (11):
  • [7] Use of Real-World Evidence to Support FDA Approval of Oncology Drugs
    Feinberg, Bruce A.
    Gajra, Ajeet
    Zettler, Marjorie E.
    Phillips, Todd D.
    Phillips, Eli G., Jr.
    Kish, Jonathan K.
    VALUE IN HEALTH, 2020, 23 (10) : 1358 - 1365
  • [8] Real-World Evidence in Oncology: Opportunities and Limitations
    Di Maio, Massimo
    Perrone, Francesco
    Conte, Pierfranco
    ONCOLOGIST, 2020, 25 (05) : E746 - E752
  • [9] ESMO Guidance for Reporting Oncology real-World evidence (GROW)
    Castelo-Branco, L.
    Pellat, A.
    Martins-Branco, D.
    Valachis, A.
    Derksen, J. W. G.
    Suijkerbuijk, K. P. M.
    Dafni, U.
    Dellaporta, T.
    Vogel, A.
    Prelaj, A.
    Groenwold, R. H. H.
    Martins, H.
    Stahel, R.
    Bliss, J.
    Kather, J.
    Ribelles, N.
    Perrone, F.
    Hall, P. S.
    Dienstmann, R.
    Booth, C. M.
    Pentheroudakis, G.
    Delaloge, S.
    Koopman, M.
    ANNALS OF ONCOLOGY, 2023, 34 (12) : 1097 - 1112
  • [10] Unmet needs in clinical nutrition in oncology: a multinational analysis of real-world evidence
    Caccialanza, Riccardo
    Goldwasser, Francois
    Marschal, Oliver
    Ottery, Faith
    Schiefke, Ingolf
    Tilleul, Patrick
    Zalcman, Gerard
    Pedrazzoli, Paolo
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2020, 12